We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
WINREVAIR Merck Sharp & Dohme (Australia) Pty Ltd
Product name
WINREVAIR
Accepted date
Jun-2025
Active ingredients
sotatercept
Proposed indication
WINREVAIR is for the treatment of adults with pulmonary arterial hypertension (when the blood pressure in the arteries which carry blood from the heart to the lungs is abnormally high)
Application type
C (new indication)
Publication date
Jun-2025